The FDA has approved Sovaldi, or sofosbuvir, Gilead Sciences' drug for the treatment of chronic hepatitis C. The drug is taken once a day and is the first approved to treat hepatitis C infection without the need for interferon. It can be used in combination with ribavirin for those with genotypes 2 and 3 infections.

Full Story:
Reuters, USA Today

Related Summaries